Coave Therapeutics Advances Novel Ophthalmic AAV Gene Therapy CoTx-101 for Retinal Vascular Diseases

Nov 18, 2025 11:28 CST Updated 11:28

Coave Therapeutics

Developer of Gene Therapies for Ophthalmic and Central Nervous System Diseases

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted must be authorized.

November 14, 2025, Coave Therapeutics ("Coave"), a company redefiningCoave Therapeutics, a company specializing in targeted gene therapy, announces its leading gene therapy project CoTx-101Nominated, used to treat retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

CompanyPlanned for 2026Completion of the TPP validation study for CoTx-101 in non-human primates，The goal is to reach IND submission readiness by 2027.

CoTx-101, utilizing Coave Therapeutics' proprietary suprachoroidal carrier (coAAV-SCS), has the potential to become a breakthrough therapy for retinal vascular diseases, combining the three key attributes of durability, efficacy, and safety, which current treatments have yet to achieve simultaneously.

Unlike other gene therapies that require invasive subretinal surgery, CoTx-101 can be administered through an outpatient procedure, targeting the back of the eye with an operation as routine as anti-VEGF injections. This therapy maintains sustained anti-angiogenic effects without the need for steroids, aiming to eliminate the need for injections in over 70% of patients with acute lymphoblastic leukemia (ALL) after one year, thereby reducing the burden of repeated injections. Unlike other treatments, CoTx-101 also avoids immune reactions triggered by the first dose, enabling treatment of both eyes.

Coave Therapeutics recently announced that it presented data at the 2025 European Society of Gene and Cell Therapy (EGSCT) Congress, demonstrating that its novel vector showed unprecedented transduction efficiency for RPE and photoreceptor cells in non-human primate studies, with the ability to evade the immune system, enabling safer and more effective treatments, and indicating potential for secondary eye therapy.

Anti-VEGF biologics are the current standard treatment for retinal vascular diseases, requiring repeated injections every 4-12 weeks, usually necessitating lifelong medication. This imposes a heavy treatment burden on patients, with over 40% discontinuing treatment after the first year, leading to uncontrolled disease progression and further vision loss. It is estimated that approximately 10 to 20 million adults globally are affected.With moistureAge-related Macular Degeneration（wAMD), 37 million people have diabetic macular edema (DME), and even more people suffer from other retinal vascular diseases.

Coave Therapeutics CEO Rodolphe Clerval commented: "The launch of our leading suprachoroidal treatment program validates our delivery-first strategy, which aims to redefine targeted gene therapy. With our first-in-class ligand-conjugated AAV, we are creating highly tissue-specific, precisely delivered, and safer vectors to advance the field of targeted gene therapy."

CoTx-101 aims to bring the ultimate treatment solution for patients with retinal vascular diseases, combining the efficacy and safety of biologics with the unique durability of gene therapy.”

Reference: Company Announcement

Scan to join the group

Mastering CAR-T Therapy, Stem Cell Therapy, Gene

Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs